Current challenges and future perspectives of iPSC-based neurotoxicity testing

  • Tsunemoto Kazunobu
    Division of Pharmacology, National Institute of Health Sciences (NIHS)
  • Yamada Shigeru
    Division of Pharmacology, National Institute of Health Sciences (NIHS)
  • Kanda Yasunari
    Division of Pharmacology, National Institute of Health Sciences (NIHS)

Bibliographic Information

Other Title
  • ヒトiPS細胞を用いた中枢神経系の安全性評価
  • 創薬シリーズ(8)創薬研究の新潮流(44)ヒトiPS細胞を用いた中枢神経系の安全性評価
  • ソウヤク シリーズ(8)ソウヤク ケンキュウ ノ シン チョウリュウ(44)ヒト iPS サイボウ オ モチイタ チュウスウ シンケイケイ ノ アンゼンセイ ヒョウカ

Search this article

Description

<p>Predicting drug-induced side effects in central nervous system is important because they can lead to the discontinuation of new drugs/candidates or the withdrawal of marketed drugs. Although many efforts are made, evaluation system using animals have not been highly predictive in humans. In addition, animal experiments are time-consuming and costly. To address these issues, in vitro evaluation methods, such as the use of New Approach Methodologies (NAM) have been explored. Human iPS cell technology has already been applied to assess drug-induced cardiotoxicity. In addition, the use of human iPS cell technology and in silico has been promoted for neurotoxicity assessment during the developmental neurotoxicity in terms of chemical safety issues. Organization for Economic Cooperation and Development (OECD) guidance regarding developmental neurotoxicity is under preparation. In this review, we will review the current trends in safety assessment methods for the central nervous system in light of these international trends.</p>

Journal

References(23)*help

See more

Related Projects

See more

Details 詳細情報について

Report a problem

Back to top